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PROTECTING VULNERABLE RESEARCH SUBJECTS:
PRACTICAL REALITIES OF INSTITUTIONAL REVIEW
BOARD REVIEW AND APPROVAL
ALISON WICHMAN, M.D.*
I. INTRODUCTION
Illnesses involving some degree of cognitive impairment, such as
stroke, some psychiatric illnesses, mental retardation, AIDS dementia
complex and many neurological diseases, are serious health problems.
For example, currently there are about four million Americans suffer-
ing from Alzheimer's disease, and the number is growing along with
the increasing age of our population. Research on these and some
other disorders presents ethical challenges because dementing and
some psychiatric illnesses compromise, or eliminate, a research sub-
ject's ability to provide valid informed consent. However, ethical con-
siderations are not limited to informed consent but include serious
concerns about our moral obligation to protect from harm some of
our society's most vulnerable individuals.
A challenge to institutions and researchers conducting research
involving cognitively impaired people is balancing the scientific mis-
sion to advance knowledge with society's mandate to protect the rights
and welfare of human subjects. Ethical guidelines, federal regula-
tions, institutional review boards (IRBs), and local institutional poli-
cies and procedures all contribute to maintaining this balance.
Prospective review and approval of research by IRBs - whose man-
date is to protect the rights and safeguard the welfare of the subjects
- is an important component of the current U.S. system of research
review and oversight. This paper will discuss IRBs' roles and responsi-
bilities, provide an overview of a policy used by IRBs at the National
Institutes of Health (NIH) when reviewing research involving cogni-
tively impaired subjects, and suggest some ways to improve IRBs' effec-
tiveness in protecting research participants.
* Deputy Director of the Office of Human Subjects Research at the National Institute
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II. CuiR'.rr ETHICAL GUIDELINES AND REGULATORY REQUIREMENTS
FOR RESEARCH INVOLVING HUMAN SUBJECTS
Biomedical and behavioral research funded or supported by the
Department of Health and Human Services (HHS), including the Na-
tional Institutes of Health (NIH), is under the purview of Tide 45 sec-
tion 46 of the Code of Federal Regulations (C.F.R.) governing the
protection of human subjects.' These regulations embody the princi-
ples of The Belmont Report -Ethical Principles and Guidelines for the Protec-
tion of Human Subjects.2 Taken together, The Belmont Report and 45
C.F.R. section 46 articulate the minimal ethical and legal obligations of
those who conduct, review and oversee research.
Forty-five C.F.R. section 46 was initially issued in 1981, however,
the core of the regulations (Subpart A), referred to as the "Common
Rule," was adopted by 15 other federal departments and agencies in
1991.' All clinical trials in the United States involving investigational
drugs are under the regulatory purview of the Food and Drug Admin-
istration (FDA) regardless of the funding source.4
A. Ethical Foundation
The ethical foundation for the current laws governing human
subject research protections is enunciated in the Belmont Report which
was issued in 1979.' It establishes three fundamental ethical princi-
ples that are relevant to all research involving human subjects - re-
spect for persons, beneficence, and justice - and demonstrates how
they are applied to the conduct of research involving human
subjects. 6
Respect for persons acknowledges the dignity and autonomy of indi-
viduals and requires that subjects give informed consent to participa-
tion in research. However, not all individuals are capable of self-
1. Regulations for Protection of Human Subjects, 45 C.F.R. § 46 (1996).
2. NAT'L COMM'N FOR THE PROTECTION OF HUMAN SUBJECTS OF BIOMEDICAL & BEHAV-
IORAL RESEARCH, THE BELMONT REPORT: ETHICAL PRINCIPLES AND GUIDELINES FOR THE PRO-
TECTION OF HUMAN SUBJECTS OF RESEARCH. GPO PUB. No. 887-809 (1979) [Hereinafter
Belmont Report].
3. In addition to HHS and the Food and Drug Administration (FDA), the following
federal departments and agencies adopted the Common Rule: the Departments of Agricul-
ture, Energy, Commerce, Housing and Urban Development, Justice, Defense, Education,
Veterans Affairs, and Transportation; the National Aeronautics and Space Administration;
the Consumer Product Safety Commission; the Agency for International Development; the
Environmental Protection Agency; the National Science Foundation and the Central Intel-
ligence Agency. The Social Security Administration is required to follow HHS regulations.
4. FDA Regulations for the Protection of Human Subjects, 21 C.F.R. §§ 50, 56 (1996).
5. Belmont Repor4 supra note 2, at 5-8.
6. Id
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determination and the Belmont Report acknowledges that people with
diminished autonomy are entitled to additional protection. For ex-
ample, some individuals may need extensive protection, even to the
point of excluding them from activities which may harm them; while
others require little protection beyond making sure they undertake
research freely, with awareness of the possible adverse consequences.7
Beneficence requires that the benefits of research be maximized
and possible harms be minimized. This principle finds expression in
a careful analysis, by researchers and institutional review boards
(IRBs), of the risks and benefits of particular research protocols.
Justice requires fair selection and treatment of research subjects.
For example, subjects should be equitably chosen to insure that cer-
tain individuals or classes of individuals are not systematically selected
for or excluded from research, unless there are scientifically or ethi-
cally valid reasons for doing so. Also, unless there is careful justifica-
tion for an exception, research should not involve persons from
groups that are unlikely to benefit directly or from subsequent appli-
cations of the research. These three principles are not mutually ex-
clusive. Each principle carries strong moral force, and difficult ethical
questions arise when they conflict. However, understanding and ap-
plying the principles of the Belmont Report helps assure that research
subjects will be treated in a respectful and ethical manner.'
B. Regulatory Requirements
HHS is the primary federal agency sponsoring biomedical and
behavioral research and includes the NIH, the FDA, the Indian
Health Service (IHS) and the Centers for Disease Control and Preven-
tion (CDC). Annually, HHS provides $5 billion for research activities
involving human subjects.9 Research must be conducted in accord-
ance with the requirements of 45 C.F.R. section 46. HHS's regulatory
apparatus for overseeing the protection of human research subjects
consists of two major tiers of review; one at the federal level and the
other at the institutional level. For example, as a condition for receipt
of HHS research funds, institutions must assure in writing that person-
nel will abide by ethical principles of the Belmont Report and the re-
7. See id. at 4.
8. See U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, GUIDELINES FOR THE CON-
DUCT OF RESEARCH INVOLVING HUMAN SUBJECTS AT THE NATIONAL INSTITUTES OF HEALTH at
19 (1995).
9. See U.S. GEN. ACCT'G OFFICE, REPORT TO THE RANKING MINORITY MEMBER, SENATE
COMM'N ON GOVERNMENTAL AFFAIRS, CONTINUED VIGILANCE CRITICAL TO PROTECTING
HUMAN SUBJECTS, GAO/HEHS Pub. No. 96-72 at 2 (1996) [hereinafter GAO Report].
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quirements of 45 C.F.R. section 46; these written documents are
referred to as Assurances of Compliance.10 There are several different
types of Assurances of Compliance, but all are contract-like agree-
ments which are negotiated and approved by the Office for Protection
from Research Risks (OPRR) on behalf of the Secretary of HHS. As
of November 1995, OPRR estimated that it held 4,847 assurances."
All assurances set forth institutional policies and procedures for the
review and monitoring of human subject research activities, including
IRB membership requirements and review and record-keeping proce-
dures.12 A variety of administrative actions can be taken by OPRR for
violation of the requirements of 45 C.F.R. section 46, or the terms and
conditions of an institution's Assurance of Compliance.' 3 For exam-
ple, OPRR may require that some or all investigators conducting re-
search under an assurance receive appropriate education concerning
the protection of human subjects, or for more serious violations, it
may recommend to HHS officials that institutions or investigators be
declared ineligible to participate in HHS-supported research (i.e., de-
barment or suspension).' 4
HHS regulations require that proposed clinical research undergo
review by an IRB, whose primary mandate is to protect the rights and
safeguard the welfare of the subjects. 5 Procedures and minimal re-
quirements for IRB review and .approval are provided in
45 C.F.R. section 46 and, in institutions with OPRR-approved assur-
ances, are also supplied in their written assurance documents. For
example, IRBs must have at least five members who have expertise in
scientific and nonscientific areas.1 6 Their membership is expected to
be diverse in order to foster a comprehensive approach to safeguard-
ing the rights and welfare of subjects (i.e., law ,ers, lay members,
bioethicists, nurses, social workers, members of the clergy). Because
normally IRBs are situated at the site of the research, members are
expected to be familiar with specific conditions affecting the conduct
of the research and the protection of the participants. For example,
10. Assurances of Compliance include Multiple Project Assurances (MPAs), Single Pro-
ject Assurances. (SPAs), and Cooperative Project Assurances (CPAs). Most major United
States research hospitals, university medical schools, and other research organizations have
MPAs which cover all human subjects research activities carried out in those organizations.
11. This includes 451 MPAs, 3,063 SPAs, and 1333 CPAs. See GAO Reprt, supra note 9,
at 8.
12. See 45 C.F.R. § 46.103 (1996).
13. See id.
14. 45 C.F.R. § 46.113.
15. See id. §§ 46.108, 46.109.
16. See id. § 46.107.
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research institutions vary in geographical location and often draw
from culturally dissimilar groups. In their deliberations, IRBs are ex-
pected to take into account the nature, content and design of the re-
search, ethical principles of the Belmont Report, and, when appropriate,
the regulatory requirements of HHS and the FDA. 7 The criteria for
IRB review and approval are provided in Table 1.18 Also, IRBs are
required to conduct continuing review of each approved research pro-
tocol at least yearly, although an IRB may request earlier evaluation if
it determines that the research presents significant physical, social, or
psychological risks to subjects." An IRB may suspend, modify, or ter-
minate approval of research that has been associated with serious
harm to subjects or is not being conducted in accord with federal reg-
ulatory requirements, ethical guidelines or institutional policies.2 °
IRBs are important because research investigators have an inher-
ent conflict of interest. As health care professionals, they are dedi-
cated to promoting the welfare of individual patients; as researchers,
they seek generalizable knowledge applicable to persons other than
their individual patients. Because the second goal may come in con-
flict with the first, our society has decided that an objective review of
human subjects research by a group of diverse individuals is most
likely to protect human subjects and promote ethically sound re-
search. Although the IRB system is not perfect, conscientious IRBs
reassure the American public that the rights and welfare of human
subjects are seriously considered by people who are not directly in-
volved in the research. It is through this process of research review
and approval that investigators, research institutions, IRB members
and others are held publicly accountable for their decisions and
actions.
C. Research Involving Vulnerable Subjects
The principle of respect for persons incorporates two ethical con-
victions: (1) that individuals should be treated as autonomous agents,
and (2) that persons with diminished autonomy are entitled to protec-
tion.21 Also, protecting human subjects with diminished autonomy is
addressed broadly in HHS regulations; "where some or all of the sub-
jects are likely to be vulnerable to coercion or undue influence, such
as children, prisoners, pregnant women, mentally disabled persons, or
17. See id. § 46.103.
18. See Appendix to this paper; see also 45 C.F.R. § 46.
19. See id. § 46.103 (b)(4).
20. See id. § 46.113.
21. See Belmont Report supra note 2, at 4.
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economically or educationally disadvantaged persons, additional safe-
guards have been included in the study to protect the rights and wel-
fare of these subjects."2 2 However, little additional, practical guidance
is provided except when pregnant women, 23 prisoners, 24 or children 25
are the subjects of research.
Vulnerable research subjects are people who are relatively or ab-
solutely incapable of protecting their interests. In other words, "they
have insufficient power, prowess, intelligence, resources, strength or
other needed attributes to protect their own interests through negoti-
ations for informed consent."26 Table 227 is a non-inclusive list of vul-
nerable, or potentially vulnerable, research subjects. It lists
individuals who have no, or limited, ability to provide informed con-
sent, as well as persons who may be particularly susceptible to undue
influence or coercion. For example, because of prisoners' restricted
liberty, serious attention must be given to the voluntariness of their
informed consent to research participation. Also, people suffering
from prolonged or serious illnesses that are refractory to standard
therapies, or for which there are no standard therapies, should be
considered vulnerable particularly when they are willing to take any
risk for even a remote possibility of relief.2s In the United States, con-
siderable controversy has surrounded research involving comatose
and critically ill people, including acute head injury and cardiopulmo-
nary resuscitation research.2 9 Not only do these individuals lack the
ability to provide informed consent, but in emergency circumstances,
there may not be time to seek consent from their representatives. The
FDA issued,"0 and HHS agreed to accept," a new regulation allowing
for waiver of informed consent by subjects or their representatives to
participation in certain emergency research studies.3 2
When reviewing research involving vulnerable or potentially vul-
nerable subjects, IRBs in consultation with investigators are expected
22. 45 C.F.R § 46.111(b).
23. Id.
24. Id.
25. Id.
26. ROBERTJ. LEVNE, ETHICS AND REGULATION OF CLINICAL RESEARCH 72 (Yale Univer-
sity Press 1988).
27. See Appendix to this paper.
28. See id.
29. See, e.g., Alison Wichman & Alan L. Sanders, Research Involving Critically Ill Subjects in
Emergency Circumstances; New Regulations, New Challenges, 48 NEUROL. 1151 (1997).
30. See Protection of Human Subjects; Informed Consent: Final rule, 61 Fed. Reg.
51,498- 51,531 (1996) (to be codified at 21 C.F.R. pts. 50, 56, 312, 314, 601, 812, 814).
31. See id. at 51,531-51,533.
32. See Wichman & Sanders, supra note 29, at 1152.
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to provide additional safeguards appropriate to the particular re-
search study under consideration.33 While this approach allows for
flexibility, it also means there may be significant variability, between
(and perhaps within) institutions, in identifying and implementing
practical safeguards.
Currently, there is no national consensus on what constitutes ap-
propriate safeguards for people with progressive dementias such as
Alzheimer's and Huntington's disease, although over the last few
years, there have been some efforts to establish consistent guide-
lines.34 However, most researchers, IRBs and research regulators ac-
knowledge that the extent of the protection afforded to research
subjects should depend on the risk of harms and the likelihood of
direct benefits to them." Therefore, when reviewing research involv-
ing cognitively impaired subjects, IRBs should take into account the
nature, degree and clinical course of the intellectual impairment; the
risks, harms and discomforts of research participation, and whether
there is prospect of direct benefit to the individual subjects. For ex-
ample, in research which exposes subjects to low risk or little discom-
fort, an IRB might decide that no additional safeguards are warranted
beyond consent by subjects' authorized representatives. However,
more stringent safeguards may be necessary for research exposing
subjects to more than minimal risk, particularly if they do not stand to
benefit directly from research participation. In fact some state stat-
utes prohibit such research.3 6 Where such a state statute does not ex-
33. See id; see also Protection of Human Subjects, 45 C.F.R.§§ 46.201-.211 (concerning
fetuses, pregnant women and human in vitro fertilization); §§ 46.301-.306 (concerning
prisoners); §§ 46.401-.409 (concerning children) (1996).
34. See Jessica Wilen Berg, Legal and Ethical Complexities of Consent with Cognitively Im-
paired Research Subjects: Proposed Guidelines, 24 J. L. MED. & ETHIcs 18 (1996); Edward W.
Keyserlingk, Proposed Guidelines for the Participants of Persons with Dementia as Research Subjects,
38 PERsP. Bio. MED. 319 (1995). See also, American College of Physicians, Cognitively Im-
paired Subjects, 111 ANNALS OF I1W. MED. 843 (1989).
35. See Keyserlink, supra note 34, at 319.
36. See, e.g, ALASKA STAT. § 47.30.830 (Michie 1996) (prohibiting experimental re-
search on state mental health patients that involve "any significant risk of physical or psy-
chological harm"); DEL. CODE ANN. tit. 16, § 51.75(f) (1995) (prohibiting any resident of a
state mental hospital from being approached "to participate in pharmaceutical research if
(the] patient is incapable of understanding the nature and consequences of [the] patient's
consent"); DEL. CODE ANN. tit. 16, § 51.74 (1995) (prohibiting certain classes of mental
hospital residents, regardless of competency, from participating in pharmaceutical re-
search); 405 ILL. CoMp. STAT. ANN. 5/2-110 (West 1993) (providing that parent or guard-
ian cannot consent to ward's participation in any "unusual, hazardous, or experimental
services" without approval by court and determination that such services are in the "best
interests" of the ward); MAss. REGS. CODE tit. 104, §§ 13.01-.05 (1995) (prohibiting re-
search on patients in mental facilities that will not provide direct, therapeutic benefit and
prohibiting research on patients with mental disabilities where the risk is more than mini-
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ist, if an IRB were to approve, such research, it might choose to
monitor the study closely, require a consent monitor, or ask the re-
searcher to implement educational activities for authorized represent-
atives about their roles and responsibilities when making research-
related decisions.
When conducting research involving vulnerable research sub-
jects, researchers and research institutions must be held to a high
standard; for example, the scientific and ethical justifications must be
particularly strong. Therefore, researchers studying vulnerable sub-
jects should be expected to provide in the protocol justifications for
the research, reasons why other (less vulnerable) subjects cannot be
studied, and identify what additional safeguards will be implemented
to protect subjects' rights and safeguard their welfare. Also, all institu-
tions or research units which conduct research involving cognitively
impaired people should have policies or written guidelines concern-
ing appropriate protections. Although the institution's IRB(s) and in-
vestigators must take into account the particular circumstances of
each individual protocol, the existence of written policies or guide-
lines demonstrates appropriate extra vigilance to the rights and wel-
fare of these vulnerable research subjects.
III. CLINICAL CENTER POLICY ON THE CONSENT PROCESS IN
RESEARCH INVOLVING COGNITIVELY IMPAIRED HUMAN
SUBJECTS
NIH's Warren G. Magnuson Clinical Center (CC) is a large
clinical research hospital with 350 beds and 13 out-patient units in
which the 900 to 1,100 research physicians change frequently. For
many years CC researchers have conducted research involving people
with cognitive impairments in order to investigate the etiology and
develop treatments of these disorders. In 1987, the CC adopted an
informed consent policy which provides additional safeguards for re-
search subjects who are, or ate likely to become, cognitively impaired
during their participation in clinical research.3 7 The development
mal and exceeds the benefit to the subject); Mo. ANN. STAT. § 6.30.115 (8) (West Supp.
1997) (preventing state mental health patients from being "the subject of experimental
research," with exceptions, and prohibiting biomedical or pharmacological research from
being performed on any individual with mental disabilities if that research will have no
direct therapeutic benefit on the individual research subject); Diane E. Hoffman & Jack
Schwartz, Proxy Consent to Participation of the Decisionally Impaired in Medical Research - May
land's Policy Initiative, 1 J. HEALTH CARE L. & POL'Y 136, nn. 9 & 12 (1997) (citing state
statutes which provide restrictions for research on the decisionally impaired).
37. See John C. Fletcher & Alison Wichman, A New Consent Policy for Research with Im-
paired Human Subjects, 23 PSyCHOPHARMACOLOGY BULL 382 (1987).
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and description of the CC policy is described in detail elsewhere 3 and
only a brief description is given here. The policy was designed to
strengthen the role of NIH's fourteen IRBs in providing additional
safeguards for:
[C] ognitively impaired human research subjects and to pro-
mote ethically appropriate research in disorders involving
cognitive impairment. The policy contains two main fea-
tures: (1) prior evaluation of proposed research studies by an
IRB to allow the appointment of surrogate decision-makers
for subjects who are or may become cognitively impaired;
and (2) an internal system of oversight and consultation
once the appointment of surrogate decision-makers is au-
thorized by the IRB. The policy recognizes eight distinct...
[research-related] cases that require additional safeguards to
the informed consent process.3 The cases incorporate sev-
eral considerations: (1) that assent4" of cognitively impaired
subjects is necessary, but not sufficient for participation in
research, (2) that the protection should be proportionate to
the risk involved, with the least protection required when re-
search involves no more than minimal risk, (3) that the Du-
rable Power of Attorney (DPA) model for the appointment
of a surrogate decision-maker is the most ethically and le-
gally supportable practice when future intellectual impair-
ment of research subjects can be predicted on the basis of
diagnosis or when existing cognitive impairment is still mild,
and (4) that degree of cognitive impairment, level of re-
search risk, and prospect of benefit to individual subjects de-
termine whether DPA or other approaches, including court
appointed guardianship, are used in selecting a surrogate de-
cision-maker.4 '
In some cases, consultation with a member of the CC Department
of Clinical Bioethics is required before research participation in order
to assure that the surrogate decision-maker understands his/her role,
and is willing and able to fulfill the responsibilities. For example, in
the CC, surrogate decisions are based on the standard of substituted
judgment which requires that the surrogate decision-maker "stand in
38. See id.
39. Among research related cases that require consideration of additional protections
are: Alzheimer's disease, schizophrenia, manias with suicidal behavior, types of aphasia,
and states of partial or total coma. See id. at 382.
40. "Assent" means an affirmative agreement to participate in research. See Regula-
tions for Protection of Human Subjects, 45 C.F.R. § 46.402(b).
41. See PhilipJ. Candilis et. al., A Survey of Researchers Using a Consent Policy for Cognitively
Impaired Human Research Subjects, 15 (6) IRB 1, 2 (1993).
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the shoes" of the incapacitated individual (and make decisions he/she
would make if able to do so). Investigators are encouraged to recruit
subjects who are not too impaired to appoint a surrogate; in that case,
prospective research subjects and surrogates can be educated about
the criteria for choosing a surrogate, that is, the need to be available
for consultation with the research team, willingness to serve.
In 1990, after the CC Policy had been in existence for three
years,42 a survey was conducted to learn more about knowledge of and
attitudes toward the policy and to evaluate whether hospital educa-
tional efforts could be designed more effectively to improve its appli-
cation.43 Also, the policy is currently undergoing review in keeping
with CC procedures to evaluate and update its research and patient
care policies on a regular basis.
IV. IMPROVING THE CURRENT IRB SYSTEM
There is no doubt that in the last 20 years significant advances
have been made in implementing protections for research subjects in
the United States. Review activities of the estimated 3,000 to 5,000
IRBs in United States universities, hospitals, private and public re-
search facilities have played an important role in educating research-
ers about, and overseeing compliance with, regulatory
requirements.44 Despite its successes, the IRB system currently is
under considerable criticism.45 Some of the criticism is deserved, and
some is not. In some instances, IRBs have become a convenient light-
ning rod for identifying what is wrong with a complex, and increas-
ingly regulated, system of clinical research. However, since the
current IRB system was put into place, the research enterprise has
changed considerably. 46 IRBs have been given more responsibili-
ties," and they have been faced with complex new issues such as ge-
netic research which have broad societal impact.
The current IRB system deserves serious reevaluation; its
strengths should be acknowledged and supported, and its weaknesses
should be addressed. However, some of the strengths of the IRB
system also contribute to its potential weaknesses. For example, hay-
42. See id.
43. See id. at 1, 3.
44. See GAO Report, supra note 9, at 6.
45. See Donald F. Phillips, Institutional Review Boards Under Stress: Will They Explode or
Change? 276 JAMA 1623 (1996).
46. See Harold Edgar & David J. Rothman, The Institutional Review Board and Beyond:
Future Challenges to the Ethics of Human Experimentation, 73 MILBANK Q. 489, 498-501 (1995).
47. See generally Phillips, supra note 46.
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ing IRBs situated at the site of the research promotes more timely
review and has the advantage of ensuring that research is reviewed by
people most likely to be familiar with the researchers and with institu-
tional and other local factors relevant to the protection of research
participants. It also provides an important on-site educational re-
source. For example, NIH has 14 IRBs consisting of about 200 mem-
bers who provide a significant educational resource to the NIH
research community. However, on-site IRB review also introduces
some potential problems. For example, a busy IRB may not engage in
ongoing educational efforts to assure that members are kept abreast
of complex ethical and regulatory issues concerning protocols it re-
views; or it may be weighted down with regulatory and paperwork re-
quirements which divert its attention away from human subject
protections; or its members may be predominately researchers, thus
depriving the IRB committee of important contributions by nonscien-
tists. An IRB's ability to fulfill its mandate is influenced by a number
of factors including the knowledge and experience of the members,
and institutional resources and commitment. IRB decisions are mat-
ters of judgment, and therefore, they depend on an understanding
and wise application of ethical guidelines and regulatory require-
ments, as well as an appreciation of local influences, such as cultural
considerations. A research study that is determined to be ethically
permissible by one IRB may not be approved by another IRB. There-
fore, efforts to improve IRBs' abilities and procedures should be
aimed at promoting consistency and thoroughness of the review pro-
cess within, and between, IRBs.
The current federal regulatory directive concerning "additional
safeguards" for vulnerable research subjects is broad and most IRBs
would benefit from additional guidance. However, it is not clear that
additional federal regulatory or state statutory requirements, such as
those currently being proposed in Maryland, 48 are necessary. There
are some educational and regulatory steps that can be taken more
quickly, and perhaps to better advantage, than legal remedies.
More practical guidance to IRBs is warranted. The current OPRR
Institutional Review Board Guidebook49 contains a chapter on research
involving cognitively impaired subjects."0 This chapter should be up-
48. Jack Schwartz, Office of the MD Att'y Gen., Second Report of the Attorney Gen-
eral's Research Working Group (May 1997) (the Second Report is reprinted in the appen-
dix to this issue of the Journal of Health Care Law & Policy).
49. OFIpcF FOR PROTECTION FROM REsEARcH Riss, U.S. DEP'T. OF HEALTH & HUMAN
SERVICES, PROTECTING HUMAN SUBJEcrs, INSTITUTIONAL REVIEW BOARD GuIDEBOOK (1993).
50. Id. at 6-33.
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dated, expanded, and re-issued either as OPRR "Points to Consider"
for IRBs or as an "OPRR Report" which is disseminated to all institu-
tions holding OPRR-approved MPAs. Also, the NIH Institutes which
fund research involving cognitively impaired subjects may choose to
issue guidelines for researchers conducting and IRBs reviewing such
research. This approach has been taken by some NIH Institutes con-
cerning the research administration of alcohol5 and drugs of abuse
52
to human subjects. If more direct action is warranted, OPRR may
choose to require MPAs to include institutional policies concerning
research involving cognitively impaired subjects. Institutions re-nego-
tiate the terms and conditions of their MPAs with OPRR every five
years. Therefore, within several years all major United States research
institutions would be required to have written policies.
Another approach to promote consistency of IRB review and to
assure serious attention to the ethical, regulatory and scientific aspects
of research involving cognitively impaired subjects is to have fewer re-
searchers conducting such research. For example, funding could be
provided only to researchers and research institutions which have
demonstrated the knowledge, res6urces, and ability to conduct the
research. The National Institute of Allergy and Infectious Diseases
(NIAID) and the National Institute of Child Health and Human De-
velopment (NICHD) have taken this approach successfully in funding
research on AIDS in both adults and children. Currently, there are
about 50 centers designated by the two institutes as pediatric AIDS
research centers. This approach has several strengths. One is that
participating centers have demonstrated the ability and necessary re-
sources, including an established iRB, to conduct clinical trials involv-
ing ill children. Also, the fact that the centers draw from diverse
ethnic groups improves the quality of the knowledge gained. Finally,
it is easier to oversee clinical trials and communicate with researchers,
IRBs and others, in a few designated research centers.
Improving the effectiveness of IRBs includes not only disseminat-
ing relevant information, but also discovering new and innovative ways
to educate IRBs dispersed throughout the United States. New educa-
tional technologies now allow for centralized, innovative ways to edu-
cate IRBs which are located throughout the United States. For
51. See NATIONAL ADVISORY COUNCIL, NATIONAL INSTITUTE ON ALCOHOL ABUSE AND AL-
COHOLISM, DEP'T OF HEALTH & HUMAN SERVICES, RECOMMENDED COUNCIL GUIDELINES ON
ETHYL ALCOHOL ADMINISTRATION IN HUMAN EXPERIMENTATION (1989).
52. See NATIONAL ADVISORY COUNCIL, NATIONAL INSTITUTE ON DRUG ABUSE, DEP'T OF
HEALTH & HUMAN SERVICES, RECOMMENDED GUIDELINES FOR THE ADMINISTRATION OF DRUGS
ro HUMAN SUBJECTS (1997).
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example, computer-based training (CBT) offers new and powerful
ways to inform and educate IRB members. NIH has some experience
with CBT. NIH's Office of Human Subjects Research (OHSR) has
designed and implemented a one hour CBT on the protection of
human subjects.5" In a pilot phase, the CBT was completed and evalu-
ated by over 2000 NIH researchers. Based on the positive results of
the pilot phase, completion of the CBT is required of all new NIH
employees who conduct research. Researchers can access the pro-
gram through the internet and also certify their completion of the
CBT electronically. NIH's experience educating researchers suggests
that CBT may be a valuable, but underutilized tool, to help inform
and educate IRBs.
An important part of OPRR's mission is to educate about and
provide clarification and guidance concerning ethical issues raised in
connection with biomedical and behavioral research involving human
subjects. OPRR's educational activities consist of disseminating infor-
mation to thousands of IRBs, researchers, and members of the public;
consultation with researchers, IRBs and IRB regulators; sponsorship
of up to six annual workshops throughout the country; and a limited
number of institutional site visits for education and technical assist-
ance. However, given the increase in the number of IRBs and the
complexity of issues facing them, new and innovative approaches to
education are warranted. This can be facilitated by NIH in two ways:
by increasing OPRR's educational staff and budget and by offering
competitive grants to fund research on innovative educational strate-
gies directed towards IRBs and researchers.
A. Improving the System Based on Knowledge: The Need for More
Research on IRBs
There is relatively little published research on IRBs when com-
pared, for example, to published literature on the educational, over-
sight and self-evaluation procedures of hospital-based clinical ethics
committees, or ethical issues in clinical medicine. In particular, pub-
lished literature or research on the effectiveness of the OPRR assur-
ance mechanism is lacking. For example, OHSR, NIH's primary
resource in its Intramural Research Program for information and edu-
cation concerning regulation and guidelines covering clinical re-
search, recently reported the results of a survey of NIH researchers
using OPRR-approved assurances in international collaborative re-
53. Available through the Office of Human Subjects Research's internet home page at
<http://helix.nih.gov:8001 /ohsr>.
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search.54 Despite the fact that OPRR has been negotiating interna-
tional assurances for over 15. years, we found no other published
information on them.
This lack of empirical information about, and research on, IRBs
can be placed in large part squarely at the feet of the federal govern-
ment, particularly HHS and the NIH. The United States system for
protecting human subjects was reviewed in 1975 by the congressio-
nally mandated National Commission for the Protection of Human
Subjects of Biomedical and Behavioral Research. Based upon recom-
mendations of the Commission, the system was substantially revised in
the late 1970s and early 1980s. It was only in 1994 that HHS began
another systematic evaluation to examine the extent to which the cur-
rent system provides adequate protection for the rights and welfare of
human subjects. Some recommendations on how to improve the sys-
tem have been provided by other groups, including the President's
Advisory Committee on Human Radiation Experiments55 and the
United States General Accounting Office. 6 Also, the Human Subject
Protections Subcommittee of the President's National Bioethics Advi-
sory Commission (NBAC) is evaluating federal departments' imple-
mentation of the Common Rule. It is expected to provide some
recommendations on steps that can be taken to improve the current
system of IRB review.
These federal efforts are laudable. However, NIH has a long his-
tory as the leader in the federal government's efforts to promulgate
human subject protections. Therefore, it has a particular responsibil-
ity to support research efforts to gain knowledge about and help im-
plement meaningful changes. Currently there are two competitive
NIH research grants to study the informed consent process in re-
search involving individuals with mental disorders57 and to identify
and validate methods for improving the informed consent process in
research.5 8 However, funding opportunities need to be broadened to
include research on IRBs, including research which enhances the
work currently being conducted by NBAC and others, and research in
areas, which although important, have received little systematic study
54. Alison Wichman et al., Collaborative Research Involving Human Subjects: A Survey of
Researchers Using International Single Projec Assurances, 19 IRB 1, at 1.
55. ADVISORY CoMMITEE ON HUMAN RADIATION EXPERIMENTS: FINAL REPORT (GPO PUB.
No. 061-000-00-848-9) (1995).
56. See GAO Report, supra note 9.
57. NATIONAL INSTITUTES OF HEALTH, Informed Consent in Clinical Mental Health Research,
Public Announcement 95-080 (1995).
58. NATIONAL INsTITUTrrFS OF HRALTH, Informed Consent in Research Involving Human Par-
ticipants, RFA No. OD-97-001 (1996).
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(e.g., the relationship of IRBs to other review groups such as Data
Safety Monitoring Boards (DSMBs), and the role of IRBs in federally
funded research conducted in foreign countries).
V. • CONCLUSION
The current debate about what constitutes ethically permissible
research involving cognitively impaired subjects is appropriate. Re-
search involving human subjects, even if they may benefit directly
from participation, is a different kind of enterprise from the routine
practice of medicine. In research, physician/researchers' goals in-
clude not only the welfare of individual research subjects, but also the
gathering of scientific data. Therefore, our society has granted a con-
ditional privilege to perform research with human subjects; the condi-
tion is that the research must be scientifically sound and conducted in
a manner that protects the rights and safeguards the welfare of the
participants.
The current United States system of protecting human research
subjects, including the role of IRBs, deserves serious and ongoing eval-
uation. The IRB system is well-developed but ever evolving. Success-
ful evolution depends on learning from the past, understanding more
about current and future needs, and applying the knowledge to im-
plement meaningful changes. Researchers, research participants and
institutions, and others, particularly the American people who bear
the burdens of research and to whom the benefits accrue, all have an
important stake in the process.
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APPENDIX
TABLE 1
CRITERIA FOR IRB APPROVAL OF RESEARCH
(adapted from 45 CFR 46.111)
(a) In order to approve research the IRB shall determine that all of
the following requirements are satisfied:
1. Risks to subjects are minimized;
2. Risks to subjects are reasonable in relation to anticipated bene-
fits, if any, to subjects and the importance of knowledge that
can reasonably be expected to result;
3. Selection of subjects is equitable taking into account the pur-
poses of the research and the setting in which the research will
be conducted. The IRB should be cognizant of the special
problems of research involving vulnerable populations;
4. Informed consent will be sought from each prospective- subject
or his/her legally authorized representative; and
5. When appropriate, adequate provisions are provided to moni-
tor data collection to assure safety of subjects and to protect the
privacy of subjects.
(b) When some or all of the subjects are likely to be vulnerable to
coercion or undue influence; .... additional safeguards have
been included in the study to protect the rights and welfare of
these subjects
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